Post hoc analysis of CREDENCE (2573 participants with type 2 diabetes and CKD): canagliflozin vs placebo reduced heart failure/CV death with low-normal sodium intake (adjHR 0.48) but not high intake (adjHR 1.05); renal benefit in both groups; no effect on all-cause death.
Secondary analysisn = 2,573
Chiriacò et al. Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial